Attached files

file filename
10-K - 10-K - Accelerate Diagnostics, Incaxdx-123119x10k.htm
EX-32 - EXHIBIT 32 - Accelerate Diagnostics, Incaxdx-12312019xexh32.htm
EX-31.2 - EXHIBIT 31.2 - Accelerate Diagnostics, Incaxdx-12312019xexh312.htm
EX-31.1 - EXHIBIT 31.1 - Accelerate Diagnostics, Incaxdx-12312019xexh311.htm
EX-21 - EXHIBIT 21 - Accelerate Diagnostics, Incaxdx-12312019xexh21.htm
EX-10.8 - EXHIBIT 10.8 - Accelerate Diagnostics, Incaxdx-12312019xexh108.htm
EX-10.7 - EXHIBIT 10.7 - Accelerate Diagnostics, Incaxdx-12312019xexh107.htm
EX-4.4 - EXHIBIT 4.4 - Accelerate Diagnostics, Incaxdx-12312019xexh44.htm


EXHIBIT 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


We consent to the incorporation by reference in the following Registration Statements:

(1)
Registration Statement (Form S-3 No. 333-217297) of Accelerate Diagnostics, Inc.,

(2)
Registration Statement (Form S-8 No. 333-187439) pertaining to the 2012 Omnibus Equity Incentive Plan of Accelerate Diagnostics, Inc.,

(3)
Registration Statement (Form S-8 No. 333-199992) pertaining to the 2012 Omnibus Equity Incentive Plan of Accelerate Diagnostics, Inc.,

(4)
Registration Statement (Form S-8 No. 333-213072) pertaining to the 2016 Employee Stock Purchase Plan of Accelerate Diagnostics, Inc.,

(5)
Registration Statement (Form S-8 No. 333-225585) pertaining to the 2012 Omnibus Equity Incentive Plan of Accelerate Diagnostics, Inc., and

(6)
Registration Statement (Form S-8 No. 333-233185) pertaining to the 2012 Omnibus Equity Incentive Plan of Accelerate Diagnostics, Inc.

of our reports dated February 27, 2020, with respect to the consolidated financial statements of Accelerate Diagnostics, Inc., and the effectiveness of internal control over financial reporting of Accelerate Diagnostics, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2019.


/s/ Ernst & Young LLP


Phoenix, Arizona
February 27, 2020